Skip to main content
P

PARADIGM BIOPHARMACEUTICALS LIMITED.. — Investor Relations & Filings

Ticker · PAR ISIN · AU000000PAR5 LEI · 984500AED3956615CA10 ASX Professional, scientific and technical activities
Open in API
Filings indexed 91 across all filing types
Latest filing 2026-04-26 Capital/Financing Update
Country AU Australia
Listing ASX PAR

About PARADIGM BIOPHARMACEUTICALS LIMITED..

https://paradigmbiopharma.com/

Paradigm Biopharmaceuticals Limited is a late-stage drug development company focused on repurposing Pentosan Polysulfate Sodium (PPS) for the treatment of inflammatory diseases and regenerative medicine. The company's primary clinical program targets Osteoarthritis (OA), where its lead candidate, Zilosul, aims to address pain and structural progression by inhibiting inflammatory pathways and promoting tissue repair. Additionally, Paradigm is exploring the efficacy of PPS in treating rare diseases such as Mucopolysaccharidosis (MPS). By leveraging the established safety profile of an existing pharmaceutical agent, the company seeks to accelerate the delivery of transformative therapies to patients with significant unmet medical needs in the musculoskeletal and lysosomal storage disorder markets. Its approach combines proprietary intellectual property with clinical data to validate PPS as a potential disease-modifying treatment.

Recent filings

Filing Released Lang Actions
Upsized $14M Placement Extends Runway Post IA 44 pages 10.4MB
Capital/Financing Update Classification · 1% confidence The document is an ASX release and accompanying investor presentation detailing a $14.0 million equity Placement and a $2.0 million Share Purchase Plan, with full terms of the capital raise, attaching options, use of proceeds, timetable, and funding strategy. This is a financing update regarding new share issuance and capital structure changes, fitting the Capital/Financing Update category (CAP).
2026-04-26 English
Proposed issue of securities - PAR 7 pages 25.7KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 3B announcement detailing a proposed issue of new securities (ordinary shares and options), including issue size, pricing, conditions, timetable, and regulatory approvals. This is a direct announcement of a share issue/capital change, matching the definition for Share Issue/Capital Change (SHA).
2026-04-26 English
Proposed issue of securities - PAR 9 pages 30.1KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 3B announcement detailing a proposed issue of securities under a securities purchase plan, including share and option issuance terms, timetables, and conditions. This aligns with a Share Issue/Capital Change announcement (SHA) rather than an earnings release, AGM material, or management report.
2026-04-26 English
March 2026 Quarterly Activities Report & Appendix 4C 11 pages 414.1KB
Interim / Quarterly Report Q3 2026
2026-04-26 English
Trading Halt 2 pages 402.0KB
Regulatory Filings Classification · 1% confidence The document is an ASX Market Announcement notifying of a trading halt at the company’s request pending a capital raising announcement. It is not a full financial report, earnings release, management discussion, or director transaction, nor does it detail the capital raise itself—only the halt pending that event. There is no bespoke category for trading halt notices, so this falls under the general regulatory announcement/fallback category. Thus, the correct classification is Regulatory Filings (RNS).
2026-04-22 English
Application for quotation of securities - PAR 6 pages 18.2KB
Regulatory Filings
2026-04-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.